SCHEMBL4803391

SCHEMBL4803391

NC(=O)c1c(-c2ccccc2)ccnc1[CH]Cc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.37
NTRK1 P04629 1/20 0.37
PIM1 P11309 1/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
TACR1 P25103 4/20 0.36
CDC7 O00311 3/20 0.36
NR3C2 P08235 1/20 0.35
CHUK O15111 2/20 0.34
GSK3B P49841 1/20 0.34
IKBKB O14920 1/20 0.34
IKBKE Q14164 1/20 0.34
PKMYT1 Q99640 1/20 0.34
CHEK2 O96017 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
FYN P06241 1/20 0.34
PLA2G10 O15496 1/20 0.33
PLA2G2A P14555 1/20 0.33
MAP2K1 Q02750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4804372 0.87 CDC7 (0.32) NTRK1PIM1CDC7NR3C2CHUK
SCHEMBL15327834 0.80 CDC7 (0.46) BCAT2NTRK1PIM1MEN1GAA
SCHEMBL4153937 0.76 GAA (0.40) NTRK1PIM1MEN1GAAKMT2A
SCHEMBL14917462 0.73 MKNK1 (0.49) BCAT2NTRK1PIM1MEN1GAA
SCHEMBL27681038 0.73 BCAT2 (0.42) BCAT2NTRK1PIM1MEN1GAA
SCHEMBL25275838 0.72 BCAT2 (0.44) BCAT2NTRK1PIM1MEN1GAA
SCHEMBL28143127 0.72 CDC7 (0.46) BCAT2NTRK1PIM1MEN1GAA
SCHEMBL23199045 0.72 NTRK1 (0.52) BCAT2NTRK1PIM1MEN1GAA
SCHEMBL1533660 0.71 NTRK1 (0.43) BCAT2NTRK1PIM1MEN1GAA
Acetic Acid SCHEMBL27846617 0.70 NTRK1 (0.50) BCAT2NTRK1PIM1MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429604-B2 Six-membered heterocycles useful as serine protease inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2008-09-30 US disclosed
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; BRISTOL-MYERS SQUIBB COMPANY 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; F12, F11, F2 BCAT2 1470/4885NTRK1 3283/4885PIM1 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.